RMTG Achieves Operational Profitability Expands Sales by 52% for Q3 Year Over Year and Reaches Gross Profit Margin of 75% for Q3
Regenerative Medical Technology Group (RMTG) has achieved operational profitability in Q3, with sales expanding by 52% from $646,828 in Q3 2023 to $986,308 in Q3 2024. The company reached a 75% gross profit margin for Q3. Patient procedures, representing 37% of revenue compared to 12% last year, increased by 370% year-over-year. RMTG is preparing to launch its Dubai clinic and plans to explore building a manufacturing facility in Cancun for exosomes, stem cells, and other biologics to enhance vertical integration.
Il Gruppo di Tecnologia Medica Rigenerativa (RMTG) ha raggiunto la redditività operativa nel terzo trimestre, con vendite in aumento del 52% passando da $646,828 nel Q3 2023 a $986,308 nel Q3 2024. L'azienda ha ottenuto un margine di profitto lordo del 75% per il terzo trimestre. Le procedure per i pazienti, che rappresentano il 37% del fatturato rispetto al 12% dell'anno scorso, sono aumentate del 370% rispetto all'anno precedente. RMTG si sta preparando a lanciare la sua clinica di Dubai e prevede di esplorare la costruzione di un impianto di produzione a Cancun per esosomi, cellule staminali e altri biologici al fine di migliorare l'integrazione verticale.
El Grupo de Tecnología Médica Regenerativa (RMTG) ha alcanzado rentabilidad operativa en el tercer trimestre, con ventas que se expandieron en un 52%, pasando de $646,828 en el Q3 2023 a $986,308 en el Q3 2024. La compañía obtuvo un margen de beneficio bruto del 75% para el tercer trimestre. Los procedimientos para pacientes, que representan el 37% de los ingresos en comparación con el 12% del año pasado, aumentaron en un 370% interanual. RMTG se está preparando para lanzar su clínica en Dubái y planea explorar la construcción de una instalación de fabricación en Cancún para exosomas, células madre y otros biológicos para mejorar la integración vertical.
재생 의료 기술 그룹 (RMTG)는 3분기에 운영 수익성을 달성했으며, 매출이 52% 증가하여 2023년 3분기 $646,828에서 2024년 3분기 $986,308로 증가했습니다. 회사는 3분기에 대해 75%의 총 이익률을 기록했습니다. 환자 절차는 작년 12%와 비교해 수익의 37%를 차지하며, 전년 대비 370% 증가했습니다. RMTG는 두바이 클리닉 개소를 준비 중이며, 칸쿤에 생물학적 제품인 엑소좀, 줄기세포 및 기타 생물 제품을 생산하기 위한 제조 시설 건설을 검토할 계획입니다.
Le Groupe de Technologie Médicale Régénérative (RMTG) a atteint la rentabilité opérationnelle au troisième trimestre, avec des ventes en augmentation de 52%, passant de 646 828 $ au T3 2023 à 986 308 $ au T3 2024. L'entreprise a atteint une marge brute de 75% pour le troisième trimestre. Les procédures pour les patients, représentant 37 % des revenus contre 12 % l'année dernière, ont augmenté de 370% d'une année sur l'autre. RMTG se prépare à ouvrir sa clinique à Dubaï et prévoit d'explorer la construction d'une installation de fabrication à Cancun pour des exosomes, des cellules souches et d'autres produits biologiques afin d'améliorer l'intégration verticale.
Die Regenerative Medizin Technologie Gruppe (RMTG) hat im dritten Quartal die operative Rentabilität erreicht, mit einem Umsatzanstieg von 52% von $646.828 im Q3 2023 auf $986.308 im Q3 2024. Das Unternehmen erreichte eine Bruttogewinnmarge von 75% im dritten Quartal. Die Patientenverfahren, die 37% des Umsatzes im Vergleich zu 12% im Vorjahr ausmachten, stiegen um 370% im Jahresvergleich. RMTG bereitet sich darauf vor, seine Klinik in Dubai zu eröffnen und plant, den Bau einer Produktionsstätte in Cancun für Exosome, Stammzellen und andere Biologika zu prüfen, um die vertikale Integration zu verbessern.
- 52% year-over-year sales growth to $986,308 in Q3 2024
- Achieved operational profitability in Q3
- 75% gross profit margin in Q3
- 370% increase in patient procedures revenue
- Patient procedures segment grew from 12% to 37% of total revenue
- None.
RMTG is pleased to announce that it has achieved operational profitability
LAS VEGAS, NV / ACCESSWIRE / November 19, 2024 / Regenerative Medical Technology Group Inc. (RMTG) ("the "Company"), a recognized leader in regenerative medicine and cellular therapies, is pleased to announce that it has achieved operational profitability (see definition below) this quarter. Also, sales expanded by
Logo
David Christensen, CEO of Regenerative Medical Technology Group said, "We are very pleased to announce our Q3 results and see our latest efforts translating into significant growth and operational profitability. Our Revenues continue to increase Year-over-Year with our patient procedures alone increasing by over
Patient procedures is the Company's fastest growing revenue segment and represents
Benito Novas, founder and CEO of Global Stem Cells Group added, "As we continue to expand revenues through our main lines of business which include training, product supplies and equipment and patient procedures and we look to launch our Dubai clinic next week, we have started to look at preliminary internal plans for building out a manufacturing facility most likely located in Cancun to manufacture exosomes, stem cells and other biologics to vertically integrate and take advantage of the expanding market for these products. Having a manufacturing facility would not only increase our margins for the same product sold but give us more control over the quality of the products we sell."
Operational profitability is defined as revenue minus all operating expenses excluding interest and taxes and is a measure of management's ability to efficiently operate the business and create operating profits.
About Regenerative Medical Technology Group
Regenerative Medical Technology Group is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group (GSCG). GSCG is an innovative provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative patient therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, GSCG is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare. The Company also distributes stem cells and other regenerative based cell lines, and equipment internationally and likewise specializes in education and training physicians in the area of regenerative medicine.
Please see this and other Company filings at www.sec.gov.
About Global Stem Cells Group
Founded by Benito Novas, Global Stem Cells Group seeks to advance the field of regenerative medicine globally. With a robust presence across continents, the organization provides both treatments and educational programs aimed at empowering doctors, researchers, and patients. Through ISSCA, GSCG conducts specialized training, certification, and hands-on workshops designed to promote best practices in the application of cellular therapies.
For more information about the Dubai clinic opening, ISSCA training event, or Global Stem Cells Group, please visit the Global Stem Cells Group website.
Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/
To learn more about Global Stem Cells Group, Inc.'s companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Company herein, including those related to the opening of the Regenerative Medicine Clinic and Laboratory and its ability to expand into the UAE markets for regenerative care, are expressly qualified in their entirety by the above-mentioned cautionary statement. The Company disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact: investor.relations@regenmedtechgroup.com
Telephone: (800) 956-3935
Contact Information
Investor Relations
Investor Relations
investor.relations@regenmedtechgroup.com
(800) 956-3935
SOURCE: Regenerative Medical Technology Group
View the original press release on accesswire.com
FAQ
What was RMTG's revenue growth in Q3 2024?
What is RMTG's gross profit margin for Q3 2024?
How much did RMTG's patient procedures revenue grow in Q3 2024?
What are RMTG's expansion plans for manufacturing?
